ReviewCardiology and therapy2026
The Pre-Kidney Transplant Cardiovascular Evaluation: A Narrative Review of Current Scientific Statements and Consensus Documents.
Review in Cardiology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease is the leading cause of mortality among individuals with kidney failure, yet evidence-based strategies to reduce cardiovascular risk in this population are limited. Kidney transplantation has been consistently shown to improve survival, including cardiovascular-specific outcomes among those with kidney failure. Substantial heterogeneity exists across transplant centers regarding the pre-transplant cardiovascular evaluation, and the evidence supporting specific testing strategies remains sparse. Current scientific guidelines and consensus statements on pre-kidney transplant cardiovascular assessment, which guide clinical practice, recommend asymptomatic testing in most individuals. However, emerging retrospective evidence suggests limited short-term benefit from routine asymptomatic screening. Ongoing randomized studies may clarify optimal strategies for repeat cardiovascular screening in waitlisted individuals who have undergone initial cardiovascular evaluation. In this review of kidney transplant candidates, we (i) examine contemporary data on cardiovascular screening (ii) highlight the diagnostic limitations of noninvasive testing in kidney failure and the lack of clear benefit from revascularization in the pre-kidney transplant setting, and (iii) outline the consequences of untimely and potentially unnecessary cardiovascular testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.